Blueprint Medicines Corporation (NASDAQ:BPMC) Director Daniel Lynch sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $63.38, for a total transaction of $316,900.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Daniel Lynch also recently made the following trade(s):

  • On Monday, September 18th, Daniel Lynch sold 2,500 shares of Blueprint Medicines Corporation stock. The shares were sold at an average price of $60.00, for a total transaction of $150,000.00.

Shares of Blueprint Medicines Corporation (NASDAQ BPMC) opened at $66.17 on Friday. The company has a current ratio of 11.28, a quick ratio of 11.28 and a debt-to-equity ratio of 0.02. Blueprint Medicines Corporation has a 1-year low of $25.08 and a 1-year high of $74.42.

Blueprint Medicines Corporation (NASDAQ:BPMC) last announced its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.06). Blueprint Medicines Corporation had a negative net margin of 437.83% and a negative return on equity of 43.11%. The company had revenue of $8.07 million for the quarter, compared to the consensus estimate of $5.35 million. During the same period last year, the firm posted ($0.62) earnings per share. The company’s revenue for the quarter was up 31.0% compared to the same quarter last year. equities analysts forecast that Blueprint Medicines Corporation will post -3.74 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/19/daniel-lynch-sells-5000-shares-of-blueprint-medicines-corporation-bpmc-stock.html.

Institutional investors and hedge funds have recently bought and sold shares of the business. TimesSquare Capital Management LLC bought a new stake in Blueprint Medicines Corporation during the 2nd quarter worth approximately $28,375,000. Bank of America Corp DE grew its holdings in Blueprint Medicines Corporation by 105.0% during the 1st quarter. Bank of America Corp DE now owns 8,090 shares of the biotechnology company’s stock worth $324,000 after acquiring an additional 4,144 shares during the last quarter. State of Wisconsin Investment Board bought a new stake in Blueprint Medicines Corporation during the 2nd quarter worth approximately $1,368,000. Wells Fargo & Company MN grew its holdings in Blueprint Medicines Corporation by 31.5% during the 2nd quarter. Wells Fargo & Company MN now owns 28,827 shares of the biotechnology company’s stock worth $1,462,000 after acquiring an additional 6,899 shares during the last quarter. Finally, Rhumbline Advisers grew its holdings in Blueprint Medicines Corporation by 62.6% during the 2nd quarter. Rhumbline Advisers now owns 43,704 shares of the biotechnology company’s stock worth $2,214,000 after acquiring an additional 16,825 shares during the last quarter. 90.83% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts have recently commented on BPMC shares. Zacks Investment Research cut shares of Blueprint Medicines Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, November 2nd. Canaccord Genuity restated a “buy” rating and issued a $56.00 target price on shares of Blueprint Medicines Corporation in a research report on Monday, September 11th. Wedbush restated an “outperform” rating and issued a $82.00 target price (up from $70.00) on shares of Blueprint Medicines Corporation in a research report on Monday, November 6th. DA Davidson assumed coverage on shares of Blueprint Medicines Corporation in a report on Friday, September 29th. They set a “buy” rating and a $90.00 price target on the stock. Finally, BidaskClub lowered shares of Blueprint Medicines Corporation from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 19th. One analyst has rated the stock with a sell rating and ten have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $70.47.

About Blueprint Medicines Corporation

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Insider Buying and Selling by Quarter for Blueprint Medicines Corporation (NASDAQ:BPMC)

Receive News & Stock Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related stocks with our FREE daily email newsletter.